|
WO2020232037A1
|
|
Antifungal agents, like ibrexafungerp for candida auris decolonization
|
|
WO2020176527A1
|
|
Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia
|
|
WO2020160316A1
|
|
Triterpenoid antifungals for the treatment of fungal osteo-articular infections
|
|
EP3735226A1
|
|
Injectable compositions of triterpenoid antifungals encapsulated in liposomes
|
|
WO2019028034A1
|
|
Antifungal agents with enhanced activity in acidic ph
|
|
CN110769854A
|
|
Antifungal agents for combined use
|
|
CA2930712A1
|
|
Antiparasitic compounds
|
|
US2014212381A1
|
|
Macrocycles
|
|
WO2012097123A2
|
|
New uses of cyclophilin inhibitors
|
|
CA2785978A1
|
|
Cyclosporine analogues
|
|
CN102869367A
|
|
Novel cyclic peptides
|
|
CA2750227A1
|
|
Cyclosporine derivative for use in the treatment of hcv and hiv infection
|
|
US2010227801A1
|
|
Pharmaceutical compositions
|
|
CN102307892A
|
|
Derivatives of cyclosporin A
|
|
GB0921210D0
|
|
2-Arylazole derivatives as antiprotozoal agents
|
|
RS53731B1
|
|
Antifungal agents
|
|
GB0910622D0
|
|
Novel amidoxime derivatives
|
|
WO2008143996A1
|
|
New chemical processes
|
|
WO2008127613A1
|
|
New pharmaceutical compositions
|
|
US2008171699A1
|
|
Cyclic peptides
|
